secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001193125-25-254571
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna reports positive Phase 2 interim data for KYV-101 in gMG; 100% response rate
--------------------------------------------------------------------------------

- 100% (6/6) of patients achieved clinically meaningful reductions in MG-ADL and QMG at 24 weeks.
- Mean reductions of -8.0 points (MG-ADL) and -7.7 points (QMG) from baseline; responses seen as early as 2 weeks.
- No high-grade CRS or ICANS observed; one SAE of Grade 4 neutropenia resolved to Grade 1.
- All patients free of nonsteroidal immunosuppressants, high-dose steroids, FcRn, and complement inhibitors.
- Company plans to initiate Phase 3 portion of KYSA-6 trial by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525254571/0001193125-25-254571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525254571/d80007d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-254571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer